Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.
暂无分享,去创建一个
[1] Michael J Gait,et al. A chemical view of oligonucleotides for exon skipping and related drug applications. , 2014, Nucleic acid therapeutics.
[2] J. Mendell,et al. Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.
[3] P. Deuss,et al. Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo , 2013, Organic & biomolecular chemistry.
[4] M. Gait,et al. Development of a general methodology for labelling peptide–morpholino oligonucleotide conjugates using alkyne–azide click chemistry† †Electronic supplementary information (ESI) available: Experimental section and supplementary figures. See DOI: 10.1039/c3cc46067c Click here for additional data file. , 2013, Chemical communications.
[5] M. Wood,et al. Splicing therapy for neuromuscular disease☆ , 2013, Molecular and Cellular Neuroscience.
[6] M. Wood,et al. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. , 2013, Human gene therapy.
[7] S. Hammond,et al. Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment , 2012, Molecular therapy. Nucleic acids.
[8] H. Moulton,et al. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. , 2012, The American journal of pathology.
[9] M. Masserini,et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[10] J. Bourke,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.
[11] F. Muntoni,et al. Targeting RNA to treat neuromuscular disease , 2011, Nature Reviews Drug Discovery.
[12] P. Camelliti,et al. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] G. van Ommen,et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.
[14] H. Moulton,et al. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. , 2010, Biochimica et biophysica acta.
[15] Chantal Pichon,et al. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers , 2009, British journal of pharmacology.
[16] B. Lebleu,et al. Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle , 2008, Nucleic acids research.
[17] P. Iversen,et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer , 2008, Proceedings of the National Academy of Sciences.
[18] P. Iversen,et al. Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure–activity studies , 2008, Nucleic acids research.
[19] H. Moulton,et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function , 2008, Human molecular genetics.
[20] P. Iversen,et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] B. Lebleu,et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide , 2007, Nucleic acids research.
[22] K. Barry Sharpless,et al. Polytriazoles as Copper(I)‐Stabilizing Ligands in Catalysis. , 2004 .
[23] P. Iversen,et al. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. , 2004, Bioconjugate chemistry.
[24] Federica Gemignani,et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues , 2002, Nature Biotechnology.
[25] R. Kole,et al. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. , 1998, Biochemistry.
[26] B. Lebleu,et al. RNA targeting in cells by peptide conjugates of peptide nucleic acids (PNA) , 2008 .
[27] D. Cistola,et al. Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. , 1995, Journal of lipid research.